Abstract
Medullary thyroid carcinoma (MTC) responds very poorly to chemotherapy. Mutations in the RET gene are critical for MTC pathogenesis. RET therefore represents a rational target for the development of novel MTC therapies. The accumulation of evidence from laboratory studies strongly suggests that PP1 inhibitor is a cytostatic agent for cells expressing RET oncoproteins. PP1 functions as a potent and selective inhibitor of RET oncoprotein phosphorylation, promoting its proteasomal degradation.
| Original language | English |
|---|---|
| Pages (from-to) | 550-552 |
| Number of pages | 3 |
| Journal | Tumori |
| Volume | 89 |
| Issue number | 5 |
| Publication status | Published - Sep 2003 |
Fingerprint
Keywords
- Medullary thyroid cancer pathogenesis
- MEN 2A
- MEN 2B
- PP1 inhibitor
- RET oncoproteins
ASJC Scopus subject areas
- Cancer Research
Cite this
Bongarzone, I., Carniti, C., Perego, C., Mondellini, P., & Pierotti, M. A. (2003). RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor. Tumori, 89(5), 550-552.